• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肉瘤样肾细胞癌的系统治疗。

Systemic therapy for sarcomatoid renal cell carcinoma.

机构信息

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

出版信息

Expert Rev Anticancer Ther. 2011 Jun;11(6):913-20. doi: 10.1586/era.11.39.

DOI:10.1586/era.11.39
PMID:21707288
Abstract

Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

摘要

肾细胞癌(RCC)是最常见的肾脏恶性肿瘤,而肉瘤样 RCC 是一种侵袭性和致命性的变体。肉瘤样特征可见于所有类型的 RCC 中,并不构成单独的组织学类型。尚未发现肉瘤样变体的任何细胞或遗传生物标志物。大多数为转移性 RCC 开发的系统治疗方法在肉瘤样 RCC 中的效果较差,尽管一些细胞毒性药物实际上可能对肉瘤样 RCC 更有效,因为其增殖速度较快。目前正在进行几项前瞻性临床试验,以研究用于治疗这种疾病的新药物组合。

相似文献

1
Systemic therapy for sarcomatoid renal cell carcinoma.肉瘤样肾细胞癌的系统治疗。
Expert Rev Anticancer Ther. 2011 Jun;11(6):913-20. doi: 10.1586/era.11.39.
2
Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.替西罗莫司治疗脑转移的肉瘤样肾细胞癌伴脑外转移得到良好控制的病例报告。
Anticancer Res. 2012 Aug;32(8):3443-7.
3
Novel therapeutics for metastatic renal cell carcinoma.转移性肾细胞癌的新型疗法
Cancer. 2009 May 15;115(10 Suppl):2361-7. doi: 10.1002/cncr.24235.
4
Update on novel agents in renal cell carcinoma.肾细胞癌新型药物治疗进展。
Expert Rev Anticancer Ther. 2009 Dec;9(12):1817-27. doi: 10.1586/era.09.157.
5
Chemotherapy for non-clear-cell renal cell carcinoma.非透明细胞肾细胞癌的化疗
Clin Genitourin Cancer. 2006 Mar;4(4):263-8. doi: 10.3816/CGC.2006.n.005.
6
Emerging drugs for renal cell carcinoma.新兴的肾癌治疗药物。
Expert Opin Emerg Drugs. 2010 Sep;15(3):343-53. doi: 10.1517/14728214.2010.486788.
7
Sorafenib for the management of advanced renal cell carcinoma.索拉非尼治疗晚期肾细胞癌。
Expert Rev Anticancer Ther. 2011 Jun;11(6):825-36. doi: 10.1586/era.11.55.
8
Treatment of metastatic renal cell carcinoma.转移性肾细胞癌的治疗
Cancer Chemother Pharmacol. 2009 Jun;64(1):11-25. doi: 10.1007/s00280-009-0983-z. Epub 2009 Apr 3.
9
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.细胞因子难治性转移性肾细胞癌的靶向治疗及社区治疗
Oncology (Williston Park). 2006 May;20(6 Suppl 5):25-8.
10
Advances in immune-based therapies of renal cell carcinoma.肾细胞癌免疫疗法的进展
Expert Rev Anticancer Ther. 2004 Dec;4(6):1081-96. doi: 10.1586/14737140.4.6.1081.

引用本文的文献

1
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.舒尼替尼与吉西他滨或舒尼替尼治疗伴肉瘤样特征的晚期肾细胞癌的随机 II 期试验结果:ECOG-ACRIN E1808。
Clin Genitourin Cancer. 2023 Oct;21(5):546-554. doi: 10.1016/j.clgc.2023.06.012. Epub 2023 Jul 3.
2
A CT-Based Radiomics Approach for the Differential Diagnosis of Sarcomatoid and Clear Cell Renal Cell Carcinoma.基于 CT 的影像组学方法在梭形细胞和透明细胞肾细胞癌鉴别诊断中的应用。
Biomed Res Int. 2020 Jul 24;2020:7103647. doi: 10.1155/2020/7103647. eCollection 2020.
3
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.
梭形细胞肉瘤样肾细胞癌的双相成分在分子上彼此相似,但与非梭形细胞肾细胞癌不同。
J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.